Drug intelligence / Profile preview

Orogen Therapeutics TNFα inhibitor

Development stage: Preclinical
Lead developer: OroGen BioSciences
Modality: Small Molecules
Administration: Oral

Overview

Orogen Therapeutics is developing a preclinical small molecule inhibitor targeting Tumor Necrosis Factor alpha (TNFα) for the treatment of rheumatoid arthritis. Discovered using the company's proprietary AI-enabled DNA-encoded library (DEL) technology platform, this program aims to provide an oral, small-molecule alternative to established biologic TNFα inhibitors. The asset features a novel composition of matter and a potentially novel mechanism of action compared to existing therapies. It is currently in the lead optimization stage of development.

Other names: TNFα small molecule inhibitor

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Orogen Therapeutics TNFα inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orogen Therapeutics TNFα inhibitor.

Explore the full profile